Table 1.
Nanoparticle-mediated drug delivery systems for pulmonary arterial hypertension treatment.
| Drug | Delivery System | Animal Model | Route of Administration | References |
|---|---|---|---|---|
| Pitavastatin | Polymer (PLGA) | MCT-induced rat model | Intratracheal | [22] |
| NF-kB decoy | Polymer (PEG-PLGA) | MCT-induced rat model | Intratracheal | [23] |
| Imatinib | Polymer (PLGA) | MCT-induced rat model | Intratracheal | [24] |
| Beraprost | Polymer (PLA and PEG-PLA) | MCT-induced rat model | Intravenous | [25] |
| Beraprost | Polymer (PLGA) | MCT-induced rat model | Intratracheal | [26] |
| Sugen/hypoxia rat model | ||||
| Fasudil | Liposome | MCT-induced rat model | Inhalation | [27] |
| AntimiRNA-145 | Liposome | Sugen/hypoxia rat model | Intravenous | [28] |
Note: NF-kB, nuclear factor kappaB; PLGA, polylactide-glycolide; PEG-PLGA, poly-(ethyleneglycol)-block-PLGA; MCT, monocrotaline; PLA, poly(lactide) homoplymer; PEG-PLA, poly-(ethyleneglycol)-PLA.